Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo

Saved in:

Bibliographic Details
Main Authors:	Ali T. Taher, Khaled M. Musallam, Vip Viprakasit, John B. Porter, Maria Domenica Cappellini
Other Authors:	American University of Beirut Medical Center
Format:	Letter
Published:	2018
Subjects:	Biochemistry, Genetics and Molecular Biology Medicine
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/33311
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later
by: Khaled M. Musallam, et al.
Published: (2022)

Treating iron overload in patients with non-transfusion-dependent thalassemia
by: Ali T. Taher, et al.
Published: (2018)

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias
by: Vip Viprakasit, et al.
Published: (2018)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
by: Ali T. Taher, et al.
Published: (2018)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox
by: Ali T. Taher, et al.
Published: (2018)

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study
by: Ali T. Taher, et al.
Published: (2018)

Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents
by: Archwin Tanphaichitr, et al.
Published: (2018)

Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies
by: Ali T. Taher, et al.
Published: (2022)

Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand
by: Maria Domenica Cappellini, et al.
Published: (2020)

Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>©</sup> )
by: Ali Taher, et al.
Published: (2020)

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Maria Domenica Cappellini, et al.
Published: (2018)

Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>©</sup> )
by: Ali Taher, et al.
Published: (2020)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
by: Ali T. Taher, et al.
Published: (2018)

Iron chelation therapy in the management of thalassemia: The Asian perspectives
by: Vip Viprakasit, et al.
Published: (2018)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
by: Taher A.T.
Published: (2023)

An overview of current treatment strategies for β-thalassemia
by: Maria Domenica Cappellini, et al.
Published: (2018)

Iron chelation therapy in the management of thalassemia: The Asian perspectives
by: Viprakasit, V., et al.
Published: (2016)

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia
by: A. T. Taher, et al.
Published: (2018)

A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
by: Maria Domenica Cappellini, et al.
Published: (2019)

Role of antioxidant and iron chelating therapies in Thalassemia patients
by: Ruchaneekorn W. Kalpravidh, et al.
Published: (2018)

MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited
by: Vip Viprakasit, et al.
Published: (2019)

Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
by: John Porter, et al.
Published: (2022)

Current approach to iron chelation in children
by: Yesim Aydinok, et al.
Published: (2018)

Gene therapy in patients with transfusion-dependent β-thalassemia
by: A. A. Thompson, et al.
Published: (2019)

Identification and key management of non-transfusion-dependent thalassaemia patients: Not a rare but potentially under-recognised condition
by: Vip Viprakasit, et al.
Published: (2018)

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
by: Vip Viprakasit, et al.
Published: (2017)

Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients
by: Natthaphat Siri-Angkul, et al.
Published: (2018)

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study
by: Ali T. Taher, et al.
Published: (2018)

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
by: M. Domenica Cappellini, et al.
Published: (2020)

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia
by: M. Domenica Cappellini, et al.
Published: (2020)

Impact of splenectomy on outcomes of hematopoietic stem cell transplantation in pediatric patients with transfusion-dependent thalassemia
by: Kleebsabai Sanpakit, et al.
Published: (2020)

Relationship between the amount of blood transfusion and the amount of iron chelation with blood and salivary ureum levels in children with beta thalassemia major
by: Pradypta, Putu Gyzca, et al.

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
by: Dudley J. Pennell, et al.
Published: (2018)

Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia
by: Ali T. Taher, et al.
Published: (2022)

Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors
by: Adisak Tantiworawit, et al.
Published: (2018)

Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors
by: Tantiworawit A., et al.
Published: (2017)

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias
by: Wai Cheng Foong, et al.
Published: (2018)

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias
by: Wai Cheng Foong, et al.
Published: (2018)

Heart rate variability for early detection of cardiac iron deposition in patients with transfusion-dependent thalassemia
by: Suchaya Silvilairat, et al.
Published: (2018)

Heart rate variability for early detection of cardiac iron deposition in patients with transfusion-dependent thalassemia
by: Silvilairat S., et al.
Published: (2017)